查看购物车
  • Traditional Chinese
  • English
欧洲疫苗佐剂市场预测至 2030 年 - 区域分析 - 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）
市场调查报告书
商品编码
1666310

欧洲疫苗佐剂市场预测至 2030 年 - 区域分析 - 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）

Europe Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
出版日期: | 出版商: The Insight Partners | 英文 93 Pages | 订单完成后即时交付

价格

2022年欧洲疫苗佐剂市值为7.405亿美元，预计到2030年将达到20.5105亿美元；预计 2022 年至 2030 年的复合年增长率为 13.6%。

兽用疫苗佐剂的批准推动欧洲疫苗佐剂市场

为动物接种常见疾病疫苗仍然是全球范围内防止动物养殖中传染病造成经济和其他损失最成功的方法。随着製造商越来越注重开发更有效、更稳定的疫苗，兽用疫苗佐剂的监管批准正在增加。 Montanide 是已知的兽用疫苗佐剂之一。 Montanide 佐剂系列以三大核心技术为基础—乳液、微乳液和聚合物。因此，兽用疫苗佐剂审批数量的激增加速了疫苗佐剂整体市场的成长。

欧洲疫苗佐剂市场概况

欧洲疫苗佐剂市场细分为德国、英国、法国、义大利、西班牙和欧洲其他地区。德国有几家顶级疫苗製造商。 2022年12月，赢创推出了名为PhytoSquene的植物基角鲨烯，以提高疫苗有效性。它是一种非动物衍生物，适用于疫苗和其他药物应用。 PhytoSquene 是已知的第一个引入市场的从苋菜油中提取的角鲨烯，用作非肠道用药的佐剂。赢创的这项最新创新旨在为市场提供可持续的、非动物衍生解决方案。 2021年，赢创推出医药级植物源胆固醇「PhytoChol」。

欧洲疫苗佐剂市场收入及 2030 年预测（百万美元）

欧洲疫苗佐剂市场区隔

欧洲疫苗佐剂市场分为佐剂类别、类型和国家。

依佐剂类别，欧洲疫苗佐剂市场分为矿物盐佐剂、乳液佐剂、脂质体佐剂等。 2022 年，矿物盐佐剂占据欧洲疫苗佐剂市场的最大份额。

根据类型，欧洲疫苗佐剂市场分为人用疫苗佐剂和兽用疫苗佐剂。 2022 年，人类疫苗佐剂部分占据了欧洲疫苗佐剂市场的较大份额。

依国家划分，欧洲疫苗佐剂市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。 2022 年，德国占据欧洲疫苗佐剂市场份额的主导地位。

Croda International Plc； CSL有限公司； Dynavax Technologies Corp；葛兰素史克公司； InvivoGen SAS； Novavax Inc.； Phibro 动物健康公司；塞皮克 SA；和 SPI Pharma Inc 是欧洲疫苗佐剂市场的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：欧洲疫苗佐剂市场 - 主要市场动态

  • 欧洲疫苗佐剂市场 - 主要市场动态
  • 市场驱动因素
    • 传染病爆发和疫情数量不断增加
    • 兽用疫苗佐剂的核准
  • 市场限制
    • 产品召回和不良影响
  • 市场机会
    • 生物技术和免疫学的进展
  • 未来趋势
    • 技术进步
  • 驱动因素和限制因素的影响：

第 5 章：疫苗佐剂市场 - 欧洲市场分析

  • 欧洲疫苗佐剂市场 - 收入和 2030 年预测
  • 欧洲疫苗佐剂市场预测与分析

第 6 章：欧洲疫苗佐剂市场分析 - 按佐剂类别

  • 概述
  • 矿物盐佐剂
  • 乳化助剂
  • 脂质体佐剂
  • 其他的

第 7 章：欧洲疫苗佐剂市场分析 - 按类型

  • 人类疫苗佐剂
  • 兽用疫苗佐剂

第 8 章：欧洲疫苗佐剂市场 - 国家分析

  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其余

第九章：产业格局

  • 概述
  • 全球疫苗佐剂市场的成长策略
  • 有机发展
    • 概述
  • 无机发展
    • 概述

第十章：公司简介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 11 章：附录

Product Code: BMIRE00031104

The Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030; it is estimated to register a CAGR of 13.6% from 2022 to 2030 .

Approvals of Veterinary Vaccine Adjuvants Drive Europe Vaccine Adjuvants Market

Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. Regulatory approvals for veterinary vaccine adjuvants are increasing, with manufacturers' growing focus on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies-emulsions, micro-emulsions, and polymers. Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.

Europe Vaccine Adjuvants Market Overview

The Europe vaccine adjuvant market has been segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. A few top vaccine manufacturers have a presence in Germany. In December 2022, Evonik launched a plant-based squalene named PhytoSquene to improve vaccine efficacy. It is a non-animal derivative suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene introduced in the market for adjuvants in drugs indicated for parenteral usage. This latest innovation of Evonik is meant to provide the market with sustainable, non-animal derivative solutions. In 2021, Evonik launched the pharma-grade and plant-derived cholesterol "PhytoChol".

Europe Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Vaccine Adjuvants Market Segmentation

The Europe vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Europe vaccine adjuvants market share in 2022.

By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Europe vaccine adjuvants market in 2022.

By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the Europe vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 Europe Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls and Adverse Effects
  • 4.4 Market Opportunities
    • 4.4.1 Advancements in Biotechnology and Immunology
  • 4.5 Future Trends
    • 4.5.1 Technological Advancements
  • 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Europe Market Analysis

  • 5.1 Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 5.2 Europe Vaccine Adjuvants Market Forecast and Analysis

6. Europe Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 6.1 Overview
  • 6.2 Mineral Salt Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Emulsion Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Liposome Adjuvant
    • 6.4.1 Overview
    • 6.4.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Human Vaccine Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Veterinary Vaccine Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Vaccine Adjuvants Market -Country Analysis

  • 8.1 Europe
    • 8.1.1 Europe Vaccine Adjuvants Market
      • 8.1.1.1 Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 Germany: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.3 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.4 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.1 Overview
        • 8.1.1.4.2 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.5 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.1 Overview
        • 8.1.1.5.2 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.6 Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.1 Overview
        • 8.1.1.6.2 Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.3 Rest of Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.6.4 Rest of Europe Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 9.3 Organic Developments
    • 9.3.1 Overview
  • 9.4 Inorganic Developments
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 SPI Pharma Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 GSK Plc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 CSL Ltd
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Seppic SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Dynavax Technologies Corp
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 InvivoGen SAS
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Croda International Plc
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Novavax Inc
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 Phibro Animal Health Corp
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners

List Of Tables

  • Table 1. Europe Vaccine Adjuvants Market Segmentation
  • Table 2. Europe Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
  • Table 3. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 4. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 5. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 6. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 8. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 9. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 10. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 11. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 12. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 13. Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 14. Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 15. Organic Developments Done by Companies
  • Table 16. Inorganic Developments Done by Companies

List Of Figures

  • Figure 1. Europe Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Europe Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 4. Europe Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 5. Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Liposome Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 10. Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Europe Vaccine Adjuvants Market - Revenue by Key Countries Revenue 2022 (US$ Million)
  • Figure 13. Europe Vaccine Adjuvants Market (2022 and 2030)
  • Figure 14. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 15. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 16. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 17. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Growth Strategies in the Vaccine Adjuvants Market